Vedithi Sundeep Chaitanya, Rodrigues Carlos H M, Portelli Stephanie, Skwark Marcin J, Das Madhusmita, Ascher David B, Blundell Tom L, Malhotra Sony
Department of Biochemistry, University of Cambridge, Tennis Court Rd., CB2 1GA, UK.
Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Parkville, VIC 3052, Australia.
Comput Struct Biotechnol J. 2020 Jan 17;18:271-286. doi: 10.1016/j.csbj.2020.01.002. eCollection 2020.
Rifampin resistance in leprosy may remain undetected due to the lack of rapid and effective diagnostic tools. A quick and reliable method is essential to determine the impacts of emerging detrimental mutations in the drug targets. The functional consequences of missense mutations in the β-subunit of RNA polymerase (RNAP) in () contribute to phenotypic resistance to rifampin in leprosy. Here, we report saturation mutagenesis of all residues in the β-subunit of RNAP to all other 19 amino acid types (generating 21,394 mutations for 1126 residues) and predict their impacts on overall thermodynamic stability, on interactions at subunit interfaces, and on β-subunit-RNA and rifampin affinities (only for the rifampin binding site) using state-of-the-art structure, sequence and normal mode analysis-based methods. Mutations in the conserved residues that line the active-site cleft show largely destabilizing effects, resulting in increased relative solvent accessibility and a concomitant decrease in residue-depth (the extent to which a residue is buried in the protein structure space) of the mutant residues. The mutations at residue positions S437, G459, H451, P489, K884 and H1035 are identified as extremely detrimental as they induce highly destabilizing effects on the overall protein stability, and nucleic acid and rifampin affinities. Destabilizing effects were predicted for all the clinically/experimentally identified rifampin-resistant mutations in indicating that this model can be used as a surveillance tool to monitor emerging detrimental mutations that destabilise RNAP-rifampin interactions and confer rifampin resistance in leprosy.
The emergence of primary and secondary drug resistance to rifampin in leprosy is a growing concern and poses a threat to the leprosy control and elimination measures globally. In the absence of an effective system to detect and monitor phenotypic resistance to rifampin in leprosy, diagnosis mainly relies on the presence of mutations in drug resistance determining regions of the gene that encodes the β-subunit of RNAP in Few labs in the world perform mouse food pad propagation of in the presence of drugs (rifampin) to determine growth patterns and confirm resistance, however the duration of these methods lasts from 8 to 12 months making them impractical for diagnosis. Understanding molecular mechanisms of drug resistance is vital to associating mutations to clinically detected drug resistance in leprosy. Here we propose an saturation mutagenesis approach to comprehensively elucidate the structural implications of any mutations that exist or that can arise in the β-subunit of RNAP in Most of the predicted mutations may not occur in due to fitness costs but the information thus generated by this approach help decipher the impacts of mutations across the structure and conversely enable identification of stable regions in the protein that are least impacted by mutations (mutation coolspots) which can be a potential choice for small molecule binding and structure guided drug discovery.
由于缺乏快速有效的诊断工具,麻风病中的利福平耐药性可能仍未被发现。一种快速可靠的方法对于确定药物靶点中出现的有害突变的影响至关重要。RNA聚合酶(RNAP)β亚基中错义突变的功能后果有助于麻风病中对利福平的表型耐药性。在此,我们报告了将RNAPβ亚基中的所有残基饱和突变为所有其他19种氨基酸类型(为1126个残基生成21394个突变),并使用基于最先进的结构、序列和正常模式分析的方法预测它们对整体热力学稳定性、亚基界面相互作用以及β亚基与RNA和利福平亲和力(仅针对利福平结合位点)的影响。位于活性位点裂隙的保守残基中的突变大多显示出不稳定作用,导致突变残基的相对溶剂可及性增加,同时残基深度(残基埋入蛋白质结构空间的程度)降低。位于S437、G459、H451、P489、K884和H1035残基位置的突变被确定为极其有害,因为它们对整体蛋白质稳定性、核酸和利福平亲和力诱导高度不稳定作用。对麻风分枝杆菌中所有临床/实验鉴定的利福平耐药突变预测了不稳定作用,表明该模型可作为一种监测工具,以监测破坏RNAP-利福平相互作用并导致麻风病中利福平耐药性的新出现的有害突变。
麻风病中对利福平的原发性和继发性耐药性的出现日益受到关注,并对全球麻风病控制和消除措施构成威胁。在缺乏检测和监测麻风病中利福平表型耐药性的有效系统的情况下,诊断主要依赖于编码麻风分枝杆菌RNAPβ亚基的rpoB基因的耐药决定区域中是否存在突变。世界上很少有实验室在有药物(利福平)存在的情况下进行麻风分枝杆菌的小鼠脚垫繁殖以确定生长模式并确认耐药性,然而这些方法的持续时间为8至12个月,使其在诊断上不切实际。了解耐药性的分子机制对于将突变与麻风病临床检测到的耐药性联系起来至关重要。在此,我们提出一种饱和诱变方法,以全面阐明麻风分枝杆菌RNAPβ亚基中存在或可能出现的任何突变的结构影响。大多数预测的突变由于适应性成本可能不会在麻风分枝杆菌中发生,但该方法产生的信息有助于解读整个结构中突变的影响,反之能够识别蛋白质中受突变影响最小的稳定区域(突变冷点),这可能是小分子结合和结构导向药物发现的潜在选择。